[HTML][HTML] Her-2 targeted therapy in advanced urothelial cancer: from monoclonal antibodies to antibody-drug conjugates
V Albarrán, DI Rosero, J Chamorro, J Pozas… - International Journal of …, 2022 - mdpi.com
Metastatic urothelial cancer, associated with a poor prognosis, is still major cause of cancer-
related death, with scarce options of effective treatment after progression to platinum-based …
related death, with scarce options of effective treatment after progression to platinum-based …
[HTML][HTML] Fucosylation in urological cancers
K Fujita, K Hatano, M Hashimoto, E Tomiyama… - International journal of …, 2021 - mdpi.com
Fucosylation is an oligosaccharide modification that plays an important role in immune
response and malignancy, and specific fucosyltransferases (FUTs) catalyze the three types …
response and malignancy, and specific fucosyltransferases (FUTs) catalyze the three types …
[HTML][HTML] A novel m7G-related genes-based signature with prognostic value and predictive ability to select patients responsive to personalized treatment strategies in …
G Lai, X Zhong, H Liu, J Deng, K Li, B Xie - Cancers, 2022 - mdpi.com
Simple Summary Although N7-methylguanosine (m7G) modification serves as a tumor
promoter in bladder cancer (BLCA), the comprehensive role of m7G-related characterization …
promoter in bladder cancer (BLCA), the comprehensive role of m7G-related characterization …
[HTML][HTML] Disease management of clinical complete responders to neoadjuvant chemotherapy of muscle-invasive bladder cancer: A review of literature
J Wu, RY Xie, CZ Cao, BQ Shang, HZ Shi… - Frontiers in …, 2022 - frontiersin.org
Muscle-invasive bladder cancer (MIBC) is an aggressive disease requiring active
management. Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is …
management. Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is …
Current state of cell therapies for genitourinary malignancies
MA Alkhouli, S Bazargan, S Pilon-Thomas… - The Cancer …, 2022 - journals.lww.com
Genitourinary (GU) cancers have greatly benefited from immunotherapy treatments, such as
immune checkpoint inhibitors. However, the durable clinical response rate for these agents …
immune checkpoint inhibitors. However, the durable clinical response rate for these agents …
[HTML][HTML] Triptolide promotes degradation of the unfolded gain-of-function Tp53R175H/Y220C mutant protein by initiating heat shock protein 70 transcription in non …
J Zhou, J Luo, P Li, Y Zhou, P Li, F Wang… - Translational Lung …, 2022 - ncbi.nlm.nih.gov
Background The mutation rate of the tumor protein P53 (TP53) has been reported to be
greater than 50% in non-small cell lung cancer (NSCLC), and gain-of-function (GOF) …
greater than 50% in non-small cell lung cancer (NSCLC), and gain-of-function (GOF) …
[HTML][HTML] Current Landscape of Immune Checkpoint Inhibitors for Metastatic Urothelial Carcinoma: Is There a Role for Additional T-Cell Blockade?
V Ogbuji, IC Paster, A Recio-Boiles, JS Carew… - Cancers, 2023 - mdpi.com
Simple Summary Immune checkpoint inhibition has played a significant role in the treatment
landscape of urothelial carcinoma due to the highly immunogenic tumor microenvironment …
landscape of urothelial carcinoma due to the highly immunogenic tumor microenvironment …
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward
A Bilé-Silva, A Lopez-Beltran, A Blanca… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Cisplatin-based chemotherapy is currently considered the gold-standard
treatment for metastatic urothelial carcinoma (mUC). Nevertheless, most mUC patients …
treatment for metastatic urothelial carcinoma (mUC). Nevertheless, most mUC patients …
[HTML][HTML] Integrated tissue and blood miRNA expression profiles identify novel biomarkers for accurate non-invasive diagnosis of breast cancer: preliminary results and …
F Su, Z Gao, Y Liu, G Zhou, Y Cui, C Deng, Y Liu… - Genes, 2022 - mdpi.com
We aimed to identify miRNAs that were closely related to breast cancer (BRCA). By
integrating several methods including significance analysis of microarrays, fold change …
integrating several methods including significance analysis of microarrays, fold change …
[HTML][HTML] Tumor microenvironment heterogeneity in bladder cancer identifies biologically distinct subtypes predicting prognosis and anti-PD-L1 responses
YF Li, Y Liu, Z Kang, J Guo, N Liu - Scientific Reports, 2023 - nature.com
Bladder cancer (BCa) is heterogeneous in the tumour microenvironment (TME). However,
the role of the TME in BCa in modulating the response to immunotherapy has not been fully …
the role of the TME in BCa in modulating the response to immunotherapy has not been fully …